According to Future Market Insights research, during the projected period, the global catheter associated urinary tract infections treatment market is expected to grow at a CAGR of 3.0%. The market value is projected to increase from US$ 1.31 Billion in 2023 to US$ 1.76 Billion by 2033. The catheter associated urinary tract infections treatment market was valued at US$ 1.26 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 3.9% in 2023.
| Attributes | Details |
|---|---|
| Market Size (2023) | US$ 1.31 Billion |
| Projected Market Value (2033) | US$ 1.76 Billion |
| Global Market Growth Rate (2023 to 2033) | 3.0% CAGR |
| Market Share of Top 5 Countries | 52.1% |
As assessed by Future Market Insights, among the drug type, quinolones held a market share of around 37.6% in the global market, in 2022. In 2022, the catheter associated urinary tract infections treatment market sales accounted for a revenue share of 72.3% in the global complicated UTI market, which was valued at around US$ 1.8 Billion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market recorded a historic CAGR of 4.1% in the last 5 years from 2017 to 2022.
Catheter associated urinary tract infections (CAUTIs) are common complications associated with use of the catheters. Elderly individuals are more susceptible to UTIs due to weakened immune systems, and urinary retentions. Moreover, individuals with compromised immune systems such as those with diabetics, or undergoing immunosuppressive therapy are at increased risk of UTIs.
These infections may also reoccur more frequently due to the body’s reduced ability to fight off the infection.
The growth of catheter associated urinary tract infections treatment market is due to the growing number of UTIs and recurrent UTIs. This has led to a higher demand for effective treatment choices.
The increasing prevalence of CAUTIs worldwide can be attributed to a variety of factors, including prolonged catheter use, inadequate catheter care and hygiene and other factors.
Patients may require catheterization for a prolonged time due to various medical conditions. Prolonged catheter use increases the opportunity for bacteria to colonise the urinary tract and cause infection. Proper maintenance and care of the urinary catheters are essential for the reduction of the infection.
Hence, the global catheter associated urinary tract infections treatment market is been driven by the high prevalence and incidence rate of the disease worldwide.
Principal Consultant
The demand for new treatment arises from the need to address antibiotic-resistant CAUTIs. As bacteria become resistant to traditional antibiotics, it becomes harder to treat these infections efficiently. This increases the risk of the implication and prolonged hospital stays for patients and adds a financial burden on the healthcare system due to the increased cost of treating drug-resistant infections.
The prevalence of antibiotic-resistant CAUTIs is a significant concern as it limits the effectiveness of traditional antibiotic therapy. Moreover, the development of new antibiotics is slow and costly, and the pipeline for novel antibiotics is relatively dry. Moreover, this can be a significant factor affecting the growth of the CAUTIs market.
The USA accounted for around 18.2% market share in the global market in 2022. The USA market’s growth is expected to rise at an overall CAGR of 2.2% over the forecast period.
Urinary tract infection is one of the most frequent infectious diseases caused by bacteria. A complicated urinary tract infection can affect anyone, regardless of gender or age, and they are caused by anatomical or functional abnormalities in the urinary system.
An increase in chronic illness such as diabetes, and kidney disease, such as renal failure and bladder cancer, is driving the usage of catheters and other drainage devices among patients and the increased use of indwelling use of urinary catheters is the attributing factor in the rise of complicated UTIs. Complicated UTIs are generally more challenging to treat compared to uncomplicated UTIs, as they are associated with more severe symptoms and have a higher risk of complication.
These are the major factors that help the market grow exponentially in the U.S., region.
The India market held around 10.2 % market share of the global market in 2022.
The large patient population in India is one of the reasons why the Indian market has a significant presence in the global catheter associated urinary tract infections treatment market.
With such a large population, the incidence and prevalence of CAUTIs are also higher.
Since CAUTI is a common healthcare-associated infection, the large patient population in India creates a high demand for CAUTIs treatment.
China held a market share of about 9.5% of the global market in 2022.
The Chinese government to improve healthcare outcomes and reduce healthcare-associated infections, including CAUTIs, has implemented several measures and programs.
The promotion of awareness and education regarding infection prevention measures is one significant initiative. The aim is to increase awareness among healthcare providers and patients about the risk associated with CAUTIs and the importance of preventing the infection.
The government provides training and education to healthcare providers to enhance their knowledge and skills in preventing CAUTIs. Additionally, they focus on this effort. In addition, supporting the adoption of infection prevention measures in healthcare facilities. China is in demand for the market of catheter-associated urinary tract infections.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Quinolones sub-segment held around 37.6% share of the global market in 2022 within the drug type.
Quinolones have a broad-spectrum antimicrobial activity. In addition, Gram-negative organism commonly causes CAUTIs, and quinolones have demonstrated efficacy against these pathogens. In addition, quinolones have the ability to achieve high concentration in the urine, which is desirable for treating urinary tract infections.
Quinolones also have good penetration in the tissue of the urinary tract, including the bladder wall, renal parenchyma and prostate gland.
They are also available in both oral and intravenous formulations providing convenience and flexibility in the treatment of CAUTIs.
The Asymptomatic CAUTI (Bacteriuria) segment held around 58.9% share of the total market in 2022 within the indication type.
In comparison to symptomatic CAUTIs, asymptomatic CAUTIs are more common. Many patients with urinary catheters may not exhibit common infection symptoms, such as fever or pain, making it difficult to detect these infections without specialized testing.
The greater prevalence of asymptomatic CAUTIs contributes to its dominant position in the indication type segment.
Retail pharmacies hold a share of about 43.2% in 2022, within the global market.
Medication used in the treatment of CAUTIs is mainly distributed through retail pharmacies, which serve as the main distribution hubs. To ensure that patients have access to necessary antibiotics and other relevant drugs, they make sure that these medications are available.
In retail settings, pharmacists and pharmacy staff offer education and counselling to patients about the correct use of medication for CAUTIs. These are the services provided by them. Retail pharmacies offer a variety of over-the-counter products that can assist in managing CAUTIs in addition to the prescribed medication.
The treatment market for catheter-associated urinary tract infections treatment is competitive. In addition to expanding their presence in emerging markets through new partnerships and merger acquisitions, market leaders are concentrating on the introduction of technologically advanced products. The competitive environment includes an analysis of a handful of global and local corporations that control the majority of the market share. In addition to acquisitions, mergers, and partnerships with key market participants.
Some key instances of development include:
Similarly, the team at Future Market Insights has tracked recent developments related to companies in the catheter associated urinary tract infections treatment market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa. |
| Key Countries Covered | USA, Canada, Brazil, Argentina, Mexico, Germany, France, UK, Italy, Spain, Russia, BENELUX, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, Northern Africa, and South Africa |
| Key Market Segments Covered | Drug Type, Indication, Distribution Channel and Region |
| Key Companies Covered |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is expected to be valued at US$ 1.31 billion in 2023.
AstraZeneca, Bayer AG, and Sanofi are the key market players.
Increased prevalence of chronic illnesses like diabetes drives catheter usage.
Retail pharmacies hold a share of about 43.2% in 2022.
The market is estimated to reach US$ 1.76 billion by 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption Analysis
4.2. Product USP Analysis
4.3. Pipeline Analysis
4.4. Regulatory Landscape, By Country
4.5. UTI Antibiotic Treatment Cycle
4.6. PESTLE Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Pharmaceutical Outlook
5.1.2. Global Healthcare Expenditure
5.1.3. Global R&D Expenditure
5.1.4. Global Complicated UTI Market Outlook (Parent Market Outlook)
5.2. Forecast Factors - Relevance & Impact
5.2.1. Technological Advancements
5.2.2. Top Companies Historical Growth
5.2.3. Entry of Top Companies
5.2.4. Prevalence of CAUTIs
5.2.5. Focus on Infection Prevention
5.2.6. Aging Population and Healthcare Demographics
5.2.7. Regulatory Policies and Guidelines
5.2.8. Technological Advancements and Innovation
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Trends Analysis By Drug Type, 2017 to 2022
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
7.3.1. Penicillin & Combinations
7.3.1.1. Amoxicillin
7.3.1.2. Amoxicillin+ Clavulanate Potassium
7.3.1.3. Others
7.3.2. Quinolones
7.3.2.1. Ciprofloxacin
7.3.2.2. Levofloxacin
7.3.2.3. Nalidixic acid
7.3.2.4. Norfloxacin
7.3.2.5. Others
7.3.3. Cephalosporin
7.3.3.1. Ceftriaxone
7.3.3.2. Cefuroxime
7.3.3.3. Cefixime
7.3.3.4. Cephalexin
7.3.4. Aminoglycoside Antibiotics
7.3.4.1. Amikacin
7.3.4.2. Gentamicin
7.3.5. Sulphonamides (Sulfamethoxazole +Trimethoprim)
7.3.6. Azoles and Amphotericin B
7.3.7. Tetracycline (Doxycycline)
7.3.8. Nitrofurans (Nitrofurantoin)
7.3.9. Other
7.4. Market Attractiveness Analysis By Drug Type
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Trends Analysis By Indication, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
8.3.1. Asymptomatic CAUTI (Bacteriuria)
8.3.2. Symptomatic CAUTI (Bacteremic)
8.4. Market Attractiveness Analysis By Indication
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Trends Analysis By Distribution Channel, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
9.3.1. Hospital Pharmacies
9.3.2. Gynecology and Urology Clinics
9.3.3. Drug Stores
9.3.4. Retail Pharmacies
9.3.5. Online Drug Stores
9.4. Market Attractiveness Analysis By Distribution Channel
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Size (US$ Million) Trend Analysis By Region, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Analysis 2017 to 2022 and Forecast 2023 to 2033
11.1. Introduction
11.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022 Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. U.S.
11.2.1.2. Canada
11.2.2. By Drug Type
11.2.3. Indication
11.2.4. Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. Indication
11.3.4. Distribution Channel
11.4. Market Trends
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
11.7. Country Level Analysis & Forecast
11.7.1. U.S. Market Analysis
11.7.1.1. Introduction
11.7.1.2. Market Analysis and Forecast By Market Taxonomy
11.7.1.2.1. By Drug Type
11.7.1.2.2. By Indication
11.7.1.2.3. By Distribution Channel
11.7.2. Canada Market Analysis
11.7.2.1. Introduction
11.7.2.2. Market Analysis and Forecast By Market Taxonomy
11.7.2.2.1. By Drug Type
11.7.2.2.2. By Indication
11.7.2.2.3. By Distribution Channel
12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. Mexico
12.3.1.2. Brazil
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Type
12.3.3. By Indication
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Type
12.4.3. By Indication
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. Mexico Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast By Market Taxonomy
12.8.1.2.1. By Drug Type
12.8.1.2.2. By Indication
12.8.1.2.3. By Distribution Channel
12.8.2. Brazil Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast By Market Taxonomy
12.8.2.2.1. By Drug Type
12.8.2.2.2. By Indication
12.8.2.2.3. By Distribution Channel
12.8.3. Argentina Market Analysis
12.8.3.1. Introduction
12.8.3.2. Market Analysis and Forecast By Market Taxonomy
12.8.3.2.1. By Drug Type
12.8.3.2.2. By Indication
12.8.3.2.3. By Distribution Channel
13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Drug Type
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Type
13.4.3. By Indication
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Germany Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast By Market Taxonomy
13.8.1.2.1. By Drug Type
13.8.1.2.2. By Indication
13.8.1.2.3. By Distribution Channel
13.8.2. Italy Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast By Market Taxonomy
13.8.2.2.1. By Drug Type
13.8.2.2.2. By Indication
13.8.2.2.3. By Distribution Channel
13.8.3. France Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast By Market Taxonomy
13.8.3.2.1. By Drug Type
13.8.3.2.2. By Indication
13.8.3.2.3. By Distribution Channel
13.8.4. U.K. Market Analysis
13.8.4.1. Introduction
13.8.4.2. Market Analysis and Forecast By Market Taxonomy
13.8.4.2.1. By Drug Type
13.8.4.2.2. By Indication
13.8.4.2.3. By Distribution Channel
13.8.5. Spain Market Analysis
13.8.5.1. Introduction
13.8.5.2. Market Analysis and Forecast By Market Taxonomy
13.8.5.2.1. By Drug Type
13.8.5.2.2. By Indication
13.8.5.2.3. By Distribution Channel
13.8.6. Russia Market Analysis
13.8.6.1. Introduction
13.8.6.2. Market Analysis and Forecast By Market Taxonomy
13.8.6.2.1. By Drug Type
13.8.6.2.2. By Indication
13.8.6.2.3. By Distribution Channel
13.8.7. BENELUX Market Analysis
13.8.7.1. Introduction
13.8.7.2. Market Analysis and Forecast By Market Taxonomy
13.8.7.2.1. By Drug Type
13.8.7.2.2. By Indication
13.8.7.2.3. By Distribution Channel
14. East Asia Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Drug Type
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Type
14.4.3. By Indication
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. China Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast By Market Taxonomy
14.8.1.2.1. By Drug Type
14.8.1.2.2. By Indication
14.8.1.2.3. By Distribution Channel
14.8.2. Japan Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast By Market Taxonomy
14.8.2.2.1. By Drug Type
14.8.2.2.2. By Indication
14.8.2.2.3. By Distribution Channel
14.8.3. South Korea Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast By Market Taxonomy
14.8.3.2.1. By Drug Type
14.8.3.2.2. By Indication
14.8.3.2.3. By Distribution Channel
15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Drug Type
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Type
15.4.3. By Indication
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. India Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast By Market Taxonomy
15.8.1.2.1. By Drug Type
15.8.1.2.2. By Indication
15.8.1.2.3. By Distribution Channel
15.8.2. Indonesia Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast By Market Taxonomy
15.8.2.2.1. By Drug Type
15.8.2.2.2. By Indication
15.8.2.2.3. By Distribution Channel
15.8.3. Malaysia Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast By Market Taxonomy
15.8.3.2.1. By Drug Type
15.8.3.2.2. By Indication
15.8.3.2.3. By Distribution Channel
15.8.4. Thailand Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast By Market Taxonomy
15.8.4.2.1. By Drug Type
15.8.4.2.2. By Indication
15.8.4.2.3. By Distribution Channel
16. Oceania Market 2017 to 2022 and Forecast 2023-2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug Type
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Type
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Australia Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast By Market Taxonomy
16.8.1.2.1. By Drug Type
16.8.1.2.2. By Indication
16.8.1.2.3. By Distribution Channel
16.8.2. New Zealand Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast By Market Taxonomy
16.8.2.2.1. By Drug Type
16.8.2.2.2. By Indication
16.8.2.2.3. By Distribution Channel
17. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
17.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.4.1. By Country
17.4.1.1. GCC Countries
17.4.1.2. Türkiye
17.4.1.3. Northern Africa
17.4.1.4. South Africa
17.4.1.5. Rest of Middle East and Africa
17.4.2. By Drug Type
17.4.3. By Indication
17.4.4. By Distribution Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Drug Type
17.5.3. By Indication
17.5.4. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
17.9. Country Level Analysis & Forecast
17.9.1. GCC Countries Market Analysis
17.9.1.1. Introduction
17.9.1.2. Market Analysis and Forecast By Market Taxonomy
17.9.1.2.1. By Drug Type
17.9.1.2.2. By Indication
17.9.1.2.3. By Distribution Channel
17.9.2. Türkiye Market Analysis
17.9.2.1. Introduction
17.9.2.2. Market Analysis and Forecast By Market Taxonomy
17.9.2.2.1. By Drug Type
17.9.2.2.2. By Indication
17.9.2.2.3. By Distribution Channel
17.9.3. Northern Africa Market Analysis
17.9.3.1. Introduction
17.9.3.2. Market Analysis and Forecast By Market Taxonomy
17.9.3.2.1. By Drug Type
17.9.3.2.2. By Indication
17.9.3.2.3. By Distribution Channel
17.9.4. South Africa Market Analysis
17.9.4.1. Introduction
17.9.4.2. Market Analysis and Forecast By Market Taxonomy
17.9.4.2.1. By Drug Type
17.9.4.2.2. By Indication
17.9.4.2.3. By Distribution Channel
18. Market Structure Analysis
18.1. Market Analysis By Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Concentration
18.4. Market Presence Analysis
18.4.1. Regional Footprint Analysis
18.4.2. Product Footprint Analysis
18.4.3. Channel Footprint Analysis
19. Competition Analysis
19.1. Competition Dashboard
19.2. Branding and Promotional Strategies, By Key Players
19.3. Key Development Analysis
19.4. Competition Deep Dive
19.4.1. Pfizer
19.4.1.1. Overview
19.4.1.2. Product Portfolio
19.4.1.3. Sales Footprint
19.4.1.4. Key Developments
19.4.1.5. SWOT Analysis
19.4.1.6. Strategy Overview
19.4.1.6.1. Marketing Strategies
19.4.1.6.2. Product Strategies
19.4.1.6.3. Channel Strategies
19.4.2. Merck & Co., Inc.
19.4.2.1. Overview
19.4.2.2. Product Portfolio
19.4.2.3. Sales Footprint
19.4.2.4. Key Developments
19.4.2.5. SWOT Analysis
19.4.2.6. Strategy Overview
19.4.2.6.1. Marketing Strategies
19.4.2.6.2. Product Strategies
19.4.2.6.3. Channel Strategies
19.4.3. GlaxoSmithKline (GSK)
19.4.3.1. Overview
19.4.3.2. Product Portfolio
19.4.3.3. Sales Footprint
19.4.3.4. Key Developments
19.4.3.5. SWOT Analysis
19.4.3.6. Strategy Overview
19.4.3.6.1. Marketing Strategies
19.4.3.6.2. Product Strategies
19.4.3.6.3. Channel Strategies
19.4.4. AstraZeneca
19.4.4.1. Overview
19.4.4.2. Product Portfolio
19.4.4.3. Sales Footprint
19.4.4.4. Key Developments
19.4.4.5. SWOT Analysis
19.4.4.6. Strategy Overview
19.4.4.6.1. Marketing Strategies
19.4.4.6.2. Product Strategies
19.4.4.6.3. Channel Strategies
19.4.5. Bayer AG
19.4.5.1. Overview
19.4.5.2. Product Portfolio
19.4.5.3. Sales Footprint
19.4.5.4. Key Developments
19.4.5.5. SWOT Analysis
19.4.5.6. Strategy Overview
19.4.5.6.1. Marketing Strategies
19.4.5.6.2. Product Strategies
19.4.5.6.3. Channel Strategies
19.4.6. Johnson & Johnson
19.4.6.1. Overview
19.4.6.2. Product Portfolio
19.4.6.3. Sales Footprint
19.4.6.4. Key Developments
19.4.6.5. SWOT Analysis
19.4.6.6. Strategy Overview
19.4.6.6.1. Marketing Strategies
19.4.6.6.2. Product Strategies
19.4.6.6.3. Channel Strategies
19.4.7. Novartis International AG
19.4.7.1. Overview
19.4.7.2. Product Portfolio
19.4.7.3. Sales Footprint
19.4.7.4. Key Developments
19.4.7.5. SWOT Analysis
19.4.7.6. Strategy Overview
19.4.7.6.1. Marketing Strategies
19.4.7.6.2. Product Strategies
19.4.7.6.3. Channel Strategies
19.4.8. Sanofi
19.4.8.1. Overview
19.4.8.2. Product Portfolio
19.4.8.3. Sales Footprint
19.4.8.4. Key Developments
19.4.8.5. SWOT Analysis
19.4.8.6. Strategy Overview
19.4.8.6.1. Marketing Strategies
19.4.8.6.2. Product Strategies
19.4.8.6.3. Channel Strategies
19.4.9. Roche Holding AG
19.4.9.1. Overview
19.4.9.2. Product Portfolio
19.4.9.3. Sales Footprint
19.4.9.4. Key Developments
19.4.9.5. SWOT Analysis
19.4.9.6. Strategy Overview
19.4.9.6.1. Marketing Strategies
19.4.9.6.2. Product Strategies
19.4.9.6.3. Channel Strategies
19.4.10. Eli Lilly and Company
19.4.10.1. Overview
19.4.10.2. Product Portfolio
19.4.10.3. Sales Footprint
19.4.10.4. Key Developments
19.4.10.5. SWOT Analysis
19.4.10.6. Strategy Overview
19.4.10.6.1. Marketing Strategies
19.4.10.6.2. Product Strategies
19.4.10.6.3. Channel Strategies
19.4.11. Bristol-Myers Squibb Company
19.4.11.1. Overview
19.4.11.2. Product Portfolio
19.4.11.3. Sales Footprint
19.4.11.4. Key Developments
19.4.11.5. SWOT Analysis
19.4.11.6. Strategy Overview
19.4.11.6.1. Marketing Strategies
19.4.11.6.2. Product Strategies
19.4.11.6.3. Channel Strategies
19.4.12. Abbott Laboratories
19.4.12.1. Overview
19.4.12.2. Product Portfolio
19.4.12.3. Sales Footprint
19.4.12.4. Key Developments
19.4.12.5. SWOT Analysis
19.4.12.6. Strategy Overview
19.4.12.6.1. Marketing Strategies
19.4.12.6.2. Product Strategies
19.4.12.6.3. Channel Strategies
19.4.13. Astellas Pharma Inc.
19.4.13.1. Overview
19.4.13.2. Product Portfolio
19.4.13.3. Sales Footprint
19.4.13.4. Key Developments
19.4.13.5. SWOT Analysis
19.4.13.6. Strategy Overview
19.4.13.6.1. Marketing Strategies
19.4.13.6.2. Product Strategies
19.4.13.6.3. Channel Strategies
19.4.14. Boehringer Ingelheim
19.4.14.1. Overview
19.4.14.2. Product Portfolio
19.4.14.3. Sales Footprint
19.4.14.4. Key Developments
19.4.14.5. SWOT Analysis
19.4.14.6. Strategy Overview
19.4.14.6.1. Marketing Strategies
19.4.14.6.2. Product Strategies
19.4.14.6.3. Channel Strategies
19.4.15. Daiichi Sankyo Company, Limited
19.4.15.1. Overview
19.4.15.2. Product Portfolio
19.4.15.3. Sales Footprint
19.4.15.4. Key Developments
19.4.15.5. SWOT Analysis
19.4.15.6. Strategy Overview
19.4.15.6.1. Marketing Strategies
19.4.15.6.2. Product Strategies
19.4.15.6.3. Channel Strategies
19.4.16. Gilead Sciences, Inc.
19.4.16.1. Overview
19.4.16.2. Product Portfolio
19.4.16.3. Sales Footprint
19.4.16.4. Key Developments
19.4.16.5. SWOT Analysis
19.4.16.6. Strategy Overview
19.4.16.6.1. Marketing Strategies
19.4.16.6.2. Product Strategies
19.4.16.6.3. Channel Strategies
19.4.17. Mylan N.V.
19.4.17.1. Overview
19.4.17.2. Product Portfolio
19.4.17.3. Sales Footprint
19.4.17.4. Key Developments
19.4.17.5. SWOT Analysis
19.4.17.6. Strategy Overview
19.4.17.6.1. Marketing Strategies
19.4.17.6.2. Product Strategies
19.4.17.6.3. Channel Strategies
19.4.18. Teva Pharmaceutical Industries Ltd.
19.4.18.1. Overview
19.4.18.2. Product Portfolio
19.4.18.3. Sales Footprint
19.4.18.4. Key Developments
19.4.18.5. SWOT Analysis
19.4.18.6. Strategy Overview
19.4.18.6.1. Marketing Strategies
19.4.18.6.2. Product Strategies
19.4.18.6.3. Channel Strategies
19.4.19. Sun Pharmaceutical Industries Ltd.
19.4.19.1. Overview
19.4.19.2. Product Portfolio
19.4.19.3. Sales Footprint
19.4.19.4. Key Developments
19.4.19.5. SWOT Analysis
19.4.19.6. Strategy Overview
19.4.19.6.1. Marketing Strategies
19.4.19.6.2. Product Strategies
19.4.19.6.3. Channel Strategies
19.4.20. Lupin Limited
19.4.20.1. Overview
19.4.20.2. Product Portfolio
19.4.20.3. Sales Footprint
19.4.20.4. Key Developments
19.4.20.5. SWOT Analysis
19.4.20.6. Strategy Overview
19.4.20.6.1. Marketing Strategies
19.4.20.6.2. Product Strategies
19.4.20.6.3. Channel Strategies
20. Assumptions and Acronyms Used
21. Research Methodology
Healthcare
March 2024
REP-GB-2533
195 pages
Explore Healthcare Insights
View Reports
Catheter Associated Urinary Tract Infections (UTI) Treatment Market
